Latest news with #healthtechnology
Yahoo
6 days ago
- Business
- Yahoo
Axmed and Every Pregnancy announce transformative partnership to enhance access to affordable essential medicines for mothers and babies affected by conflict and crisis
WASHINGTON, July 17, 2025 /PRNewswire/ -- Axmed, a health technology venture revolutionizing access to medicines and health products through an innovative procurement platform, and Every Pregnancy, a global, faith-based coalition that provides health services to mothers and babies affected by conflict and crisis, today announced a strategic partnership to bring affordable, quality medicines to mothers and babies who need them most. Approximately 92% of maternal deaths occur in low- and middle-income countries. In these regions, pregnant women are dying from preventable causes due to lack of access to and high costs of essential medicines and health supplies. Families in low-income countries often pay more than double for the same medicines as families in high-income settings. This new collaboration will provide Every Pregnancy partners access to affordable and quality medicines through Axmed's pioneering B2B marketplace. Together, Every Pregnancy and Axmed will break down systemic barriers that prevent medicines from reaching mothers and newborns – including fragmented supply chains, missed demand, and the limited purchasing power of local NGOs who are best positioned to meet the needs of local populations. "No mother or newborn should die simply because of where they live or how much they earn," said Emmanuel Akpakwu, Founder & CEO of Axmed. "Through our partnership with Every Pregnancy, we're combining cutting-edge procurement and supply technology with a powerful network of frontline maternal health providers to drive systemic change – faster, smarter, and at the scale this crisis demands." Through its tech-enabled procurement platform, Axmed aggregates demand from public, private, and nonprofit health care procurers, enabling bulk purchasing directly from qualified manufacturers and drastically reducing costs and improving the quality of products. By partnering with Every Pregnancy, Axmed extends its platform's reach and impact in over 20 countries with high burdens of maternal mortality – including Nigeria, Sudan, Pakistan, Palestine, and more. "This is what it looks like when community power and innovation work hand-in-hand," said Isra Chaker, CEO of Every Pregnancy. "Our collaboration with Axmed is about more than access – it's about equity, justice, and building responsive health care systems that save lives." The Axmed–Every Pregnancy partnership marks a turning point in equitable health care delivery for moms and babies, so that one day, every mother and child will have access to the quality care they deserve. About Axmed: Axmed is a technology-enabled marketplace revolutionizing how medicines and health products are sourced, financed, procured, and delivered across low- and middle-income countries. By digitizing large-scale procurement and aggregating demand across diverse procurers, Axmed enables direct access to a trusted network of local and international prequalified suppliers. Visit About Every Pregnancy: Every Pregnancy is a faith–inspired initiative committed to ensuring safe pregnancies and healthy newborns in areas impacted by conflict or crisis. The organization unites a coalition of over 40 faith–inspired philanthropists and NGOs across the U.S., U.K., Canada, Pakistan, Yemen, and beyond. Visit Media inquiries: info@ or comms@ Photo - View original content to download multimedia: SOURCE Axmed; Every Pregnancy Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
National Post
7 days ago
- Business
- National Post
OBIO® Paves the Way for Companies to Succeed in Canada as a Stepping Stone to New Global Markets
Article content TORONTO — OBIO ®, a not-for-profit, membership-based organization offering programming and infrastructure to support early-stage and venture-backed companies, announces the launch of its Health Commercialization Access Program to accelerate the growth of Canadian biotechnology and health technology companies. The Program is supported by the Government of Canada, through the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), as part of a $5-million investment in OBIO ®. Article content FedDev Ontario has long championed OBIO ® to assist high-potential health and life sciences companies to grow, scale up and attract global investment. Over the past decade, OBIO ® has enabled over 350 companies to generate in excess of $150 million in sales and $200 million in foreign direct investment. Through its Early Adopter Health Network (EAHN ™) and by accelerating technology commercialization, post-seed financing and strategic partnerships via its Capital Access Advisory Program (CAAP ®), OBIO ® has been helping Canadian innovators establish a beachhead in our publicly-funded healthcare systems. Article content Through its programming, OBIO ® identifies early-stage companies that are well-positioned to develop their businesses in Canada and expand to countries on other continents. OBIO's EAHN ™ program, which includes more than 80 healthcare organizations and health systems across Canada, has developed a pipeline of companies selling their products successfully in the Canadian market. Commercial success in Canada puts companies in a prime position to sell to international jurisdictions. Many OBIO ® affiliated-companies have already gone on to export their technologies to Europe, Indo-Pacific, Latin America and the Caribbean, and the Middle East and North Africa. Article content OBIO's Health Commercialization Access Program provides integrated CAAP ® and EAHN ™ programming for early-stage life sciences and health tech companies. This enables OBIO ® to provide its technical expertise to advise companies and allow them to leverage OBIO's extensive and expanding network of industry and health science ecosystem partners in Canada. By gaining a foothold in the Canadian market, OBIO ® enables innovators to meet the growing demand for quality, home-grown medical products and lay the foundation for a healthier future. Article content 'Congratulations to OBIO ® on the launch of the Health Commercialization Access Program,' said the Honourable Evan Solomon, Minister of Artificial Intelligence and Digital Innovation and Minister responsible for the Federal Economic Development Agency for Southern Ontario. 'This program is a powerful catalyst for Canadian innovation. OBIO ® plays a critical role in helping homegrown health tech and biotech companies turn breakthrough ideas into real-world impact. Our government is proud to support the talent, ingenuity, and ambition of Canada's innovators as they develop cutting-edge technologies that improve lives and strengthen our health system.' Article content 'We are thrilled to support early-stage life sciences and health tech companies to build a beachhead in Canada and diversify their target markets at this time of changing global trade relationships,' said Dr. Maura Campbell, President and CEO of OBIO ®. The precision psychiatry company, Mobio Interactive, has benefited from OBIO's programming to support commercialization in Canada and beyond. 'Our mission is to help create a world where anyone who is living anywhere with mental health issues has the opportunity to access clinically meaningful support,' said Dr. Bechara Saab, Mobio Interactive's CEO & Chief Scientist. 'OBIO's CAAP ® provided us with key introductions to investors whose support enabled us to lengthen our runway and scale our business. Later, we took part in OBIO's EAHN ™ to collaborate with Canadian healthcare organizations to gather real-world data on the effectiveness of our technology. Those collaborations led to sustained revenues and also provided the proof cases we needed to build partnerships in Singapore and other Asian countries.' Article content Flosonics Medical is a venture-backed start-up that develops and commercializes wearable sensors to improve the clinical management of critically ill patients inside and outside the hospital. 'EAHN ™ gave us the opportunity to evaluate our novel ultrasound technology in a real-world setting,' said Joe Eibl, CEO of Flosonics Medical, which partnered with Health Sciences North in Sudbury to conduct an accelerated study on the use of FloPatch. 'Our successful participation in the program was a pivotal moment that accelerated our path to a North American launch. Trying to raise funds and prepare for commercialization during a period of uncertainty is always challenging. Our involvement in both CAAP ® and EAHN ™ signaled to current and prospective investors that we were not only building momentum but doing so with validated clinical impact.' Article content About OBIO ® Article content Founded in 2009, OBIO ® is a not-for-profit, membership-based organization engaged in strategy, programming, policy development and advocacy to address the needs of the next generation of companies developing innovative human health products. OBIO ® supports early-stage and venture-backed life sciences and health tech companies enabling them to raise capital, hire and train industry-ready talent, facilitate the commercialization and market adoption of their technologies in health systems, and access infrastructure. OBIO® advances this goal through collaborative partnerships with industry, the investment community, academia, the healthcare system and government. For more information, please visit and follow OBIO ® on LinkedIn and X. Article content About FedDev Ontario Article content For over 15 years, the Government of Canada, through FedDev Ontario, has worked to advance and diversify the southern Ontario economy through funding opportunities and business services that support innovation, growth and job creation in Canada's most populous region. The Agency has delivered impressive results, which can be seen in southern Ontario businesses that are creating innovative technologies, improving productivity, growing revenues, creating jobs, and in the economic advancement of communities across the region. Learn more about the impact the Agency is having in southern Ontario by exploring our investment profiles, our Southern Ontario Spotlight, and FedDev Ontario's X, Facebook, Instagram and LinkedIn accounts. Article content Article content Article content Article content Article content Contacts Article content
Globe and Mail
08-07-2025
- Health
- Globe and Mail
Masimo Joins Innovators' Network at American Heart Association Center for Health Technology & Innovation
Masimo (NASDAQ: MASI), a global medical technology company that develops and manufactures innovative noninvasive monitoring solutions, has joined the American Heart Association Center for Health Technology & Innovation's (the Center) Innovators' Network. The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions. This press release features multimedia. View the full release here: Masimo is a member of the American Heart Association's Innovators' Network The Innovators' Network is a health care technology consortium that connects entrepreneurs, providers, researchers, and payers. Innovators' Network members also have the opportunity to access the Association's digital evidence-based scientific guidelines and clinical recommendations as they develop digital healthcare technologies. Members collaborate with the Center in different ways, including building models for clinical outcome studies (which lowers the significant cost of developing those studies independently), helping connect the science to technology, and providing evidence that a digital platform improves healthcare outcomes – a key concern for providers and payers. 'The Center aims to advance the rapid, efficient, and effective development of healthcare technology,' said Robert A. Harrington, M.D., FAHA, volunteer past president of the American Heart Association (2019-2020), chair of the American Heart Association's Health Tech Advisory Group for the Center and the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine and provost for medical affairs of Cornell University. 'Joining the Innovators' Network gives members the opportunity to leverage the consortium and work toward broadening and deepening their engagement in this arena.' Daniel Cantillon, MD, Chief Medical Officer at Masimo, commented, 'We're proud to join the American Heart Association Innovators' Network to ensure that our next generation of cardiovascular and brain health monitoring solutions address critical unmet needs – especially for the most vulnerable patients in historically underserved communities.' @Masimo | #Masimo About Masimo Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve life, improve patient outcomes, reduce the cost of care, and take noninvasive monitoring to new sites and applications. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown to outperform other pulse oximetry technologies in over 100 independent and objective studies, which can be found at Masimo SET® is estimated to be used on more than 200 million patients around the world each year and is the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2025 Newsweek World's Best Hospitals listing. Additional information about Masimo and its products may be found at Forward-Looking Statements This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements other than statements of historical facts that address activities, events or developments that we expect, believe or anticipate will or may occur in the future. These forward-looking statements include, among others, statements regarding Masimo joining the American Heart Association Center for Health Technology & Innovation; strategic and other potential benefits of becoming a member of the Center for Health Technology & Innovation; Masimo's development of its existing products or any new product solutions; and other matters that do not relate strictly to historical facts or statements of assumptions underlying any of the foregoing. These statements are often identified by the use of words such as 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'on-going,' 'opportunity,' 'plan,' 'potential,' 'predicts,' 'forecast,' 'project,' 'seek,' 'should,' 'will,' or 'would,' the negative versions of these terms and similar expressions or variations, but the absence of such words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: our ability to effectively protect our intellectual property from competitors; our ability to allocate sufficient time resources toward our relationship with the Center for Health Technology & Innovation; obtaining regulatory approval of our current and future products and technologies; and other factors discussed in the 'Risk Factors' section of our most recent periodic reports filed with the Securities and Exchange Commission ('SEC'), including our most recent Form 10-K and Form 10-Q, all of which you may obtain for free on the SEC's website at Forward-looking statements are not guarantees of future performance. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the 'Risk Factors' contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Times
04-07-2025
- Health
- Times
Scotland told to learn from England's NHS ‘doctor in pocket'
SNP ministers have been told they must 'learn lessons' from England's NHS app, after Sir Keir Starmer outlined plans for a supercharged version before Scotland's has even launched. The prime minister promised patients south of the border 'a doctor in your pocket' as part of plans to make the technology, which has already been in use in England for more than six years, an 'indispensable' part of everyday life. Wes Streeting, the UK health secretary, has said the technology will become 'critical national infrastructure' for Britain, offering health advice and including detailed digitised patient records and potentially live video chats with consultants and bespoke health coaching. In contrast, an app for the Scottish health service, first announced in 2021, is not expected to launch on a trial basis until December. Its functionality will be severely restricted initially, when its sole practical purpose will be allowing dermatology patients in just one area, Lanarkshire, to receive appointment letters. The lack of progress in Scotland has been branded a 'national embarrassment' with the SNP facing questions over why it did not seek to adapt England's technology for the devolved health service, rather than insisting on developing its own version. Stephen Kerr, the Tory MSP, said: 'The Scottish government's approach to delivering a simple NHS app for patients has been expensive, incompetent and frankly insulting to those who just want reliable access to their own health records and services. 'They have spent £17 million with nothing meaningful delivered except delays, excuses and a narrow pilot limited to one specialty in one health board. 'Instead of wasting yet more time and money reinventing the wheel for separatist political reasons, ministers should work constructively with the UK government to give people in Scotland access to the NHS app that is already up and running in England. 'Patients deserve joined-up systems that work — not a vanity project stuck in perpetual development.' The NHS app in England, which has 35 million users, already allows patients to book appointments at GP services, order prescriptions and manage hospital appointments. Denmark introduced a digital system two decades ago. This week, Starmer told an audience of frontline NHS staff in east London that private industries had revamped their offerings dramatically around apps and that the NHS should be no different. He said: 'We will transform the NHS app so it becomes an indispensable part of life for everyone. It will become, as technology develops, like having a doctor in your pocket, providing you with 24-hour advice, seven days a week.' The 'supercharged' version of the app is promised in England by 2028, with other goals including video calls with consultants, AI advice on symptoms and personalised lifestyle advice and health coaching. Meanwhile, the app in Scotland, the functionality of which remains unclear, is not set to fully roll out nationally until 2030. Chris Williams, vice chair of the Royal College of General Practitioners Scotland, said that although 'we have waited a long time,' he remained supportive of the approach taken by Scotland to develop its own app, citing the 'significant differences' in how NHS systems and records are structured. He said he did not believe it would be possible for the NHS England app to 'simply be used in the Scottish healthcare setting' and that different priorities would make it 'less applicable'. He added: 'There are lessons to be learned from the English example and avoiding creating extra pressure in general practice, especially in regard to managing the lifelong records of patients, that in some cases will contain historical information with language and terminology that belongs in the past. 'People in Scotland currently have 24/7 access to information about health and services via the NHS Inform website. We understand that there is a review taking place of the NHS Inform website that will lead to improvements to ensure that information is relevant, up-to-date and checked by subject matter experts.' A Scottish government spokesman said: 'The NHS England app was developed to support England's NHS trusts and is configured specifically to their IT infrastructure. We have, however, already engaged extensively with NHS England and with other health systems, to explore how we can take learning from other approaches in developing our service. 'Scotland's planned online app is for both health and social care and we will launch it in Lanarkshire by the end of 2025. National rollout will commence through 2026, and we will publish a national rollout plan later this summer.'
Khaleej Times
18-06-2025
- Health
- Khaleej Times
Inside UAE's most advanced cancer centre: Wearables, robotic surgery, carbon-ion therapy
From real-time patient monitoring and robotic surgery to genomic screening and heavy-ion therapy, Cleveland Clinic Abu Dhabi's Fatima bint Mubarak Center is progressing how cancer is diagnosed, treated, and prevented in the UAE. Marking its second anniversary, the centre's leadership presented a series of updates that reflect the growing scale and sophistication of the country's cancer care infrastructure. "We've treated over 27,000 cancer patients since inception," said Dr Stephen Grobmyer, Chief of the Cancer Institute. "But what's more exciting is where we're going." Wearables and cooling devices Among the most immediate changes affecting patients today is the roll-out of the BioButton, a medical-grade wearable that remotely tracks a patient's vital signs after chemotherapy or surgery. "We're putting it on almost all patients who start on chemotherapy," Dr Grobmyer confirmed, adding that it allows clinicians to identify signs of deterioration early and proactively intervene. "We can detect early warning signs like increased temperature or heart rate before the patient even notices. One of our patients, for example, was starting to experience complications like nausea and vomiting. We contacted them before it escalated, brought them in for fluids, and they were able to return home without hospital admission." The centre is also investing in supportive technologies to preserve the quality of life during treatment. Cooling caps, used to reduce chemotherapy-related hair loss, have already shown tangible results. "I had a patient last week who finished chemotherapy and still had almost all of her hair. She was very happy about that," said Dr Grobmyer. For patients facing neuropathy, a side effect of some cancer medications, cooling gloves are being used to reduce nerve damage in hands and feet. Robotic surgery = smaller cuts, faster recovery Dr Usman Ahmad, division chair of Thoracic Surgery, Heart, Vascular and Thoracic Institute, explained how Cleveland Clinic Abu Dhabi has made robotic and minimally invasive surgery the new norm for cancer patients across specialities. "There is no surgical treatment for which the patients have to leave the UAE now," he said. He emphasised the dramatic improvement in recovery times through robotic surgery. "Instead of big incisions, we operate through keyholes. Patients start walking the same day or the next, go home in a few days, and can start further treatment like chemotherapy or immunotherapy within a week or two." He described the shift from older surgical methods in vivid terms: "The robotic technology is so advanced that the instruments act like my hands inside the patient's body, without me having to put my hands inside. Traditional thoracic surgery might require an incision this big," he said, gesturing from his heart to the abdomen area. "Now, we do the entire operation through incisions the size of a fingertip." Dr Ahmad noted that nearly all types of cancer surgeries, including for lung, stomach, oesophagus, kidney, prostate, and ovarian cancers, are now performed robotically. "We don't compromise on safety or quality. These are the same standards you'd find in the US or Europe." AI, adaptive radiation and heavy ion therapy Radiation oncology has also seen a leap forward, with Cleveland Clinic Abu Dhabi now offering AI-powered adaptive radiation and brachytherapy, internal radiation delivered directly to the tumour. "Adaptive radiation is among the most advanced in the world," said Dr Fady Geara, Division Chair of Radiation Oncology. "We adjust the radiation in real-time during treatment to follow the tumour's exact position and spare healthy tissue." He added that this is especially useful for abdominal and pelvic cancers, where organs shift frequently. The centre's brachytherapy programme is now operating daily and, according to Dr Geara, is often "not even available in many US centres." As previously announced, the facility is preparing to launch the region's first carbon-ion therapy centre - a treatment for tumours resistant to traditional methods. "We're building a new facility to house the synchrotron accelerator," said Dr Geara. "We aim to treat our first patient in two to three years, or possibly sooner." Genomics, prevention, and regional leadership A polygenic risk score (PRS) study to predict breast cancer in patients without known genetic mutations is also underway. "Most global data is from Western populations," said Dr Fawad Khan, Staff Physician for Longevity Medicine. "We're now validating this in Emiratis, which will also benefit the wider Arab population." The hospital's longevity and high-risk prevention programmes already serve hundreds of patients, both survivors and those with elevated risk, including international patients from Saudi Arabia and Qatar. "This is not a branch of Cleveland Clinic," Dr. Grobmyer emphasised. "We are Cleveland Clinic. Our tumour boards include our colleagues in Ohio, and our goal is not just to take from the system but to contribute new knowledge back." Training the next generation As part of that long-term vision, the centre has received approval to launch a four-year oncology residency programme starting in 2026. "Our preference is to train locals - Emirati doctors, but we also bring in candidates from the wider region when needed," said Dr Grobmyer. He noted that the programme, accredited through the UAE's board system, is designed to match the standards of top US fellowships. "It's a long journey," he added, describing the structure as a progression from internal medicine training to subspecialty practice in solid tumour oncology and malignant haematology. Once trainees complete the full programme and pass board exams, "they will be independently able to manage the full spectrum of diseases," he explained, Dr Ahmad stressed how early detection saves lives, and no one in the UAE needs to leave the country for treatment as they could receive timely, high-quality, sufficient treatment in the capital. "While our technology is world-class, it's only useful if people get to us in time," he concluded.
